Rallybio News

Rallybio Analyst Ratings

Benzinga00:21

J.P. Morgan Securities: Reiterates the Rallybio (RLYB.US) rating and adjusted from superior to superior market rating, with a target price of $8.00.

Zhitong FinanceApr 19 01:21

Rallybio Analyst Ratings

BenzingaApr 19 01:17

JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target

BenzingaApr 19 01:18

Buy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT Treatment

TipRanksApr 18 07:15

Rallybio Analyst Ratings

BenzingaApr 11 21:59

Wedbush Sticks to Their Buy Rating for Rallybio (RLYB)

TipRanksApr 11 20:15

Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)

TipRanksApr 11 18:30

Buy Rating Affirmed for Rallybio on Back of JNJ Collaboration and FNAIT Program Progress

TipRanksApr 11 08:35

Rallybio's RLYB212 Positioned to Transform FNAIT Prophylaxis Market, Analyst Maintains Buy Rating

TipRanksMar 27 01:55

Rallybio's Clinical Advancements and Solid Financials Earn a Buy Rating From Analyst Ritu Baral

TipRanksMar 14 05:35

JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target

BenzingaMar 13 23:49

Rallybio Analyst Ratings

BenzingaMar 13 19:18

Buy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market Potential

TipRanksMar 13 18:25

Buy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial Stability

TipRanksMar 13 05:55

Jefferies Cuts Rallybio to Hold, Cites Lack of Near-term Catalysts

Seeking AlphaFeb 8 00:54

Wedbush Adjusts Rallybio's Price Target to $13 From $14, Keeps Outperform Rating

MT NewswiresFeb 7 21:59

Analysts' Top Healthcare Picks: Rallybio (RLYB), Madrigal Pharmaceuticals (MDGL)

TipRanksFeb 7 21:02

Jefferies Downgrades Rallybio to Hold, Lowers Price Target to $1.5

BenzingaFeb 7 20:02

Rallybio Analyst Ratings

BenzingaFeb 7 19:25